チャールズ・リバー・ラボの戦略調査とボード変更は,25.5%のYTD減少にもかかわらず,その株を22%増した. Charles River Labs' strategic review and board changes boosted its stock by 22%, despite a 25.5% YTD decline.

Charles Riversationsは戦略評価とボード変更を発表し,その結果22%の株式の急上昇が生じた. Charles River Laboratories announced a strategic review and board changes, leading to a 22% stock surge. 同社は,DSAセグメントの純予約の改善により,わずかに減少した収益を背景に,FY25の見通しを更新し,株当たり4.35ドルから4.85ドルの利益と,株当たり9.30ドルから9.80ドルの調整された利益を予測した. The company updated its FY25 outlook, projecting earnings of $4.35 to $4.85 per share and adjusted earnings of $9.30 to $9.80 per share, on a slightly declining revenue due to improved net bookings in its DSA segment. 株価は増加したものの,同期以来25.5%減少している. Despite the stock increase, it is still down 25.5% year-to-date.